PP
VRTX icon

Paloma Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Paloma Partners’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2,400
Closed -$1.12M – 1710
2024
Q2 		$1.12M Buy
+2,400
New +$1.04M 0.03% 485
2022
Q4 		– Sell
-1,100
Closed -$318K – 1170
2022
Q3 		$318K Buy
+1,100
New +$316K 0.01% 612
2018
Q3 		– Sell
-1,300
Closed -$221K – 1968
2018
Q2 		$221K Buy
+1,300
New +$202K ﹤0.01% 1430

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Paloma Partners's VRTX Position: Q2 2025 in Review

Paloma Partners sold out of Vertex Pharmaceuticals (VRTX) in Q2 2025, closing a stake of 840 shares — an estimated $407K sold.

Paloma Partners first reported a position in VRTX in Q2 2013 and held it in 36 quarters. The position peaked at $10.3M in Q4 2014. 1,562 funds tracked by Wall St. Rank hold VRTX as of Q2 2025.

  • Paloma Partners reported no remaining Vertex Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Paloma Partners sold 840 Vertex Pharmaceuticals shares in Q2 2025, an estimated $407K.
  • Paloma Partners first reported a position in Vertex Pharmaceuticals in Q2 2013 and held it in 36 quarters.
  • Paloma Partners's Vertex Pharmaceuticals position peaked at $10.3M in Q4 2014.
  • 1,562 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2025.

Based on Paloma Partners's 13F filing for Q2 2025, filed 14 Aug 2025.